Bacteriophages are viruses that can infect bacteria and multiply within them, breaking down the cell and destroying the bacteria - amplifying themselves in the process to deal with more bacteria.
They are found everywhere including in river water, soil, sewage and on the human body. Soon after their initial discovery in 1915, bacteriophages were investigated as antibacterial therapeutic agents. A limited understanding of their mode of action meant early work was often unsuccessful and with the advent of the chemical antibiotic era, bacteriophages were passed over as therapeutics.
Dr Harper, Chief Scientific Officer at AmpliPhi Bioscience in Bedfordshire explains why bacteriophages are being revisited as antibacterial agents. "Each bacteriophage is highly specific to a certain type of bacteria and needs the right bacterial host cell in order to multiply. The more bacterial targets there are, the quicker they grow by killing the host cells. Therefore it seems very likely that infections harbouring high numbers of bacteria will benefit most from bacteriophage therapy – for example chronically infected ears, lungs and wounds," he said.
"For these types of infection, only a tiny dose of the virus is needed - as small as one thousandth of a millionth of a gram. This can usually be administered directly to the site of infection in a spray, drops or a cream. The major advantage to bacteriophages is that they don't infect human cells so seem likely to be very safe to use."
Increasing resistance to antibiotics has meant that bacterial infections are becoming more and more difficult to treat. With fewer antibiotics available to treat drug-resistant infections, research into bacteriophage therapy has been accelerated. "The rate of new antibiotics coming onto the market does not match the rate of increasing drug-resistance. The need for new approaches to counter such high resistance is both urgent and vital. New approaches will save lives," stressed Dr Harper.
Clinical trials for bacteriophage therapy are now underway. The first clinical trial for safety was reported in 2005 and the results demonstrating the effectiveness of bacteriophage therapy were published in 2009. This clinical trial was conducted by AmpliPhi. The company is planning further clinical trials in conditions where existing antibacterial therapies are not able to help. "With the results of further clinical trials, once regulatory issues are overcome and future investment secured in this area of research, this should lead to the development of novel products suitable for widespread use to tackle bacterial diseases and overcome antibiotic resistance", said Dr Harper.
Laura Udakis | EurekAlert!
Single-stranded DNA and RNA origami go live
15.12.2017 | Wyss Institute for Biologically Inspired Engineering at Harvard
New antbird species discovered in Peru by LSU ornithologists
15.12.2017 | Louisiana State University
DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.
Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...
MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.
Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...
Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...
Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.
To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...
The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.
Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
15.12.2017 | Power and Electrical Engineering
15.12.2017 | Materials Sciences
15.12.2017 | Life Sciences